Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 3/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344379 | 0.83 | CTSS (0.39) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL9409854 | 0.80 | KIF11 (0.42) | — | |
| SCHEMBL15413442 | 0.78 | JAK3 (0.37) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2732000 | 0.78 | TDP1 (0.35) | CTSSCTSKCTSBCTSLCA12 | |
| SCHEMBL4420857 | 0.78 | ATM (0.55) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL13731820 | 0.76 | CTSS (0.58) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL15021100 | 0.76 | CTSS (0.58) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL7401688 | 0.76 | CTSL (0.41) | CTSSCTSKCTSBCTSLCA12 | |
| SCHEMBL12204041 | 0.74 | NPY5R (0.55) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL7269259 | 0.74 | EPHX1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-9029406-B2 | N-carboxyalkylauristatins and use thereof | SEATTLE GENETICS, INC (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2686336-B1 | N-CARBOXYALKYL-AURISTATINS AND USE THEREOF | SEATTLE GENETICS INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140080763-A1 | N-CARBOXYALKYLAURISTATINS AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CTSS 336/4885CTSK 318/4885CTSB 299/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CTSS 336/4885CTSK 318/4885CTSB 299/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CTSS 336/4885CTSK 318/4885CTSB 299/4885 |
| US-20140080763-A1 | N-CARBOXYALKYLAURISTATINS AND USE THEREOF | HGFAC, HGF, MET | CTSS 1454/4885CTSK 1730/4885CTSB 1382/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CTSS 336/4885CTSK 318/4885CTSB 299/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | CTSS 336/4885CTSK 318/4885CTSB 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.